stockrowOwlet, Inc.
OWLT Healthcare Medical Devices
Owlet, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $105.7 million, up 35.4% from fiscal 2024.
- Revenue
- +29.9%
- EPS
- +97.9%
- Free cash flow
- +55.7%
- Total debt
- −16.9%
Quarter to June 2026, against a year earlier
Follow OWLT
Alert me
Owlet, Inc. (OWLT) Piotroski F-score
Owlet, Inc.'s Piotroski F-score for fiscal 2025 is 4 out of 9: 4 of nine tests of profitability, leverage and efficiency passed, down from 5 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 4 | (1.00) |
| FY2024 | 5 | (1.00) |
| FY2023 | 6 | 5.00 |
| FY2022 | 1 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (61.96%) | (36.79%) | Fail | 0 |
| Positive operating cash flow | (10.79m) | (11.21m) | Fail | 0 |
| Rising return on assets | (61.96%) | (36.79%) | Fail | 0 |
| Cash flow above net income | 31.06m | 6.01m | Pass | 1 |
| Falling long-term leverage | 0.04 | 0.09 | Pass | 1 |
| Rising current ratio | 1.85 | 1.27 | Pass | 1 |
| No new shares issued | 18,094,000 | 10,951,000 | Fail | 0 |
| Rising gross margin | 50.64% | 50.36% | Pass | 1 |
| Rising asset turnover | 1.56 | 1.67 | Fail | 0 |
| Piotroski F-score | Mixed | 4 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| INGN Inogen, Inc compare | 5 |
| ZOMDF Zomedica Corp. compare | 4 |
| OWLT Owlet, Inc. | 4 |
| APYX Apyx Medical Corporation compare | 4 |
| LUCD Lucid Diagnostics Inc. compare | 4 |
| QTRX Quanterix Corporation compare | 3 |
| LUNG Pulmonx Corporation compare | 3 |
| CATX Perspective Therapeutics, Inc. compare | 3 |
| MXCT MaxCyte, Inc. compare | 2 |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover